David R. Guyer, M.D. and Anthony P. Adamis, M.D. resigned from EyePoint Pharmaceuticals' Board, and Fred Hassan was appointed as a new director with a compensation package including a cash retainer and stock options.
AI Assistant
EYEPOINT PHARMACEUTICALS INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.